Anthropic Coefficient Bio acquisition: $400M stock deal for healthcare AI

Anthropic has reportedly completed the acquisition of stealth biotech AI startup Coefficient Bio in a $400 million stock transaction, according to multiple industry reports confirmed April 3, 2026. Anthropic Coefficient Bio acquisition: The deal is valued at about $400M and is structured as stock rather than cash, signaling confidence in the long-term valuation of vertical AI in healthcare and life sciences. Coefficient Bio’s leadership and team are expected to join Anthropic’s health and life sciences division. The startup, founded by Samuel Stanton and Nathan C. Frey (both previously at Genentech’s Prescient Design), focuses on computational drug discovery using machine learning plus domain-specific biological knowledge. The company aims to reduce drug discovery time and cost by improving analysis of complex biological data. Integration plans: Coefficient Bio’s work is expected to enhance Anthropic’s Claude for Life Sciences platform. That product allows researchers to interact with complex biological data via natural language, and the added drug-discovery capabilities could expand tools for target identification, compound screening, and clinical-trial optimization. Market context: The healthcare AI sector is crowded, with big tech (e.g., Google, Microsoft, NVIDIA) and pharma AI players such as Recursion Pharmaceuticals, Insilico Medicine, and BenevolentAI competing for leadership. Analysts note the premium for specialized AI talent. Regulatory angle: FDA evaluation frameworks for AI medical technologies remain a wildcard, but Anthropic’s investment suggests growing confidence that clearer pathways will emerge. Anthropic Coefficient Bio acquisition may accelerate biotech AI consolidation, pressure smaller startups, and intensify competition among larger players, affecting deal flow and long-term sentiment around healthcare-focused AI.